Low colonic absorption drugs: risks and opportunities in the development of oral extended release products-Reference-Cited by-同舟云学术

Low colonic absorption drugs: risks and opportunities in the development of oral extended release products

Published:2017-10-14 Issue:2 Volume:15 Page:197-211
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Xu Jin¹,Lin Yiqing¹,Boulas Pierre¹,Peterson Matthew L.¹

Affiliation:

1. Pharmaceutical Development, Biogen Inc, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2018.1389889

Reference136 articles.

1. Transit of pharmaceutical dosage forms through the small intestine.

2. Connor A, King G, Jones K Evaluation of human regional bioavailability to assess whether modified release development is feasible, http://mms.technologynetworks.net/posters/510.pdf. Accessed August 30, 2014.

3. Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches of formulation bridging in support of orally administered drug product development;International Journal of Pharmaceutics;2022-12

2. The Advances and Biomedical Applications of Imageable Nanomaterials;Frontiers in Bioengineering and Biotechnology;2022-07-05

3. Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience;Drug Development and Industrial Pharmacy;2022-03-04

4. Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices;Therapeutic Delivery;2021-10

5. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review;European Journal of Pharmaceutical Sciences;2021-07